Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Swiss HIV Cohort Study.
Discontinuation of primary prophylaxis against toxoplasma encephalitis was studied in 199 HIV-1-infected patients on antiretroviral combination treatment who had experienced a sustained increase in their CD4 count. During a follow-up of 272 person-years, no cases of toxoplasma encephalitis arose.
Furrer
H
H
Opravil
M
M
Bernasconi
E
E
Telenti
A
A
Egger
M
M
D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control*; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D018890:Chemoprevention; D015331:Cohort Studies; D016001:Confidence Intervals; D004660:Encephalitis / Q000469:parasitology* / Q000517:prevention & control; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy; D015497:HIV-1; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013557:Switzerland; D016781:Toxoplasmosis, Cerebral / Q000517:prevention & control*
D019380:Anti-HIV Agents; D000890:Anti-Infective Agents